Kamal SM - Search Results

1

Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study.

Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, Aziz IA, Fathelbab IF, Mansour HM. Kamal SM, et al. Am J Gastroenterol. 2014 Feb;109(2):199-211. doi: 10.1038/ajg.2013.427. Epub 2014 Jan 21. Am J Gastroenterol. 2014. PMID: 24445571

2

The accuracy and cost-effectiveness of hepatitis C core antigen assay in the monitoring of anti-viral therapy in patients with chronic hepatitis C genotype 4.

Kamal SM, Kassim S, El Gohary E, Fouad A, Nabegh L, Hafez T, Bahnasy K, Hassan H, Ghoraba D. Kamal SM, et al. Aliment Pharmacol Ther. 2015 Aug;42(3):307-18. doi: 10.1111/apt.13261. Epub 2015 May 27. Aliment Pharmacol Ther. 2015. PMID: 26018116 Free article.

3

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

Kamal SM, Ahmed A, Mahmoud S, Nabegh L, El Gohary I, Obadan I, Hafez T, Ghoraba D, Aziz AA, Metaoei M. Kamal SM, et al. Liver Int. 2011 Mar;31(3):401-11. doi: 10.1111/j.1478-3231.2010.02435.x. Epub 2011 Jan 11. Liver Int. 2011. PMID: 21281434 Clinical Trial.

4

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M. Kamal SM, et al. Hepatology. 2007 Dec;46(6):1732-40. doi: 10.1002/hep.21917. Hepatology. 2007. PMID: 17943989 Clinical Trial.

5

Viral hepatitis a to e in South mediterranean countries.

Kamal SM, Mahmoud S, Hafez T, El-Fouly R. Kamal SM, et al. Mediterr J Hematol Infect Dis. 2010 Feb 10;2(1):e2010001. doi: 10.4084/MJHID.2010.001. Mediterr J Hematol Infect Dis. 2010. PMID: 21415943 Free PMC article.

6

Acute hepatitis C: a systematic review.

Kamal SM. Kamal SM. Am J Gastroenterol. 2008 May;103(5):1283-97; quiz 1298. doi: 10.1111/j.1572-0241.2008.01825.x. Am J Gastroenterol. 2008. PMID: 18477352 Review.

7

Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response.

Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, Ezzat W, Koziel M. Kamal SM, et al. Gastroenterology. 2001 Sep;121(3):646-56. doi: 10.1053/gast.2001.27024. Gastroenterology. 2001. PMID: 11522749

8

Improving outcome in patients with hepatitis C virus genotype 4.

Kamal SM. Kamal SM. Am J Gastroenterol. 2007 Nov;102(11):2582-8. doi: 10.1111/j.1572-0241.2007.01538.x. Epub 2007 Sep 26. Am J Gastroenterol. 2007. PMID: 17900328 Review.

9

Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.

Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH. Kamal SM, et al. Gastroenterology. 2006 Mar;130(3):632-8. doi: 10.1053/j.gastro.2006.01.034. Gastroenterology. 2006. PMID: 16530503 Clinical Trial.

10

Hepatitis C genotype 4 therapy: increasing options and improving outcomes.

Kamal SM. Kamal SM. Liver Int. 2009 Jan;29 Suppl 1:39-48. doi: 10.1111/j.1478-3231.2008.01930.x. Liver Int. 2009. PMID: 19207965 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page